Metachromatic Leukodystrophy Medication

1. Gieselmann V, Krägeloh-Mann I. Metachromatic leukodystrophy--an update. Neuropediatrics. 2010 Feb. 41(1):1-6. [QxMD MEDLINE Link]. [Full Text].

2. Köhler W, Curiel J, Vanderver A. Adulthood leukodystrophies. Nat Rev Neurol. 2018 Feb. 14(2):94-105. [QxMD MEDLINE Link]. [Full Text].

3. van Rappard DF, Boelens JJ, Wolf NI. Metachromatic leukodystrophy: Disease spectrum and approaches for treatment. Best Pract Res Clin Endocrinol Metab. 2015 Mar. 29 (2):261-73. [QxMD MEDLINE Link]. [Full Text].

4. Elgün S, Waibel J, Kehrer C, et al. Phenotypic variation between siblings with metachromatic leukodystrophy. Orphanet J Rare Dis. 2019 Jun 11. 14(1):136. [QxMD MEDLINE Link]. [Full Text].

5. van Rappard DF, Königs M, Steenweg ME, Boelens JJ, Oosterlaan J, van der Knaap MS, et al. Diffusion tensor imaging in metachromatic leukodystrophy. J Neurol. 2018 Mar. 265 (3):659-668. [QxMD MEDLINE Link]. [Full Text].

6. van Rappard DF, Klauser A, Steenweg ME, Boelens JJ, Bugiani M, van der Knaap MS, et al. Quantitative MR spectroscopic imaging in metachromatic leukodystrophy: value for prognosis and treatment. J Neurol Neurosurg Psychiatry. 2018 Jan. 89 (1):105-111. [QxMD MEDLINE Link]. [Full Text].

7. Gomez-Ospina N. Arylsulfatase A Deficiency. Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, Amemiya A, eds. GeneReviews® [Internet]. [updated 2020 Apr 30]. Seattle, WA: University of Washington; 2006 May 30. [Full Text].

8. Anlar B, Waye JS, Eng B. Atypical clinical course in juvenile metachromatic leukodystrophy involving novel arylsulfatase A gene mutations. Dev Med Child Neurol. 2006 May. 48(5):383-7. [QxMD MEDLINE Link]. [Full Text].

9. von Figura K, Gieselman V, Jaeken J. Metachromatic leukodystrophy. Scriver C, Beadet A, Valle D, Sly W, et al, eds. The Metabolic and Molecular Bases of Inherited Disease. 8th ed. New York, NY: McGraw-Hill Professional; 2001. 3695-3724.

10. Hettiarachchi D, Dissanayake VHW. Three novel variants in the arylsulfatase A (ARSA) gene in patients with metachromatic leukodystrophy (MLD). BMC Res Notes. 2019 Nov 6. 12(1):726. [QxMD MEDLINE Link]. [Full Text].

11. Wang Y, Chen X, Liu C, Wu S, Xie Q, Hu Q, et al. Metachromatic leukodystrophy: Characterization of two (p.Leu433Val, p.Gly449Arg) arylsulfatase A mutations. Exp Ther Med. 2019 Sep. 18(3):1738-1744. [QxMD MEDLINE Link]. [Full Text].

12. Doherty K, Frazier SB, Clark M, Childers A, Pruthi S, Wenger DA, et al. A closer look at ARSA activity in a patient with metachromatic leukodystrophy. Mol Genet Metab Rep. 2019 Jun. 19:100460. [QxMD MEDLINE Link]. [Full Text].

13. Beerepoot S, van Dooren SJM, Salomons GS, et al. Metachromatic leukodystrophy genotypes in The Netherlands reveal novel pathogenic ARSA variants in non-Caucasian patients. Neurogenetics. 2020 Oct. 21(4):289-299. [QxMD MEDLINE Link]. [Full Text].

14. Wu S, Hou M, Zhang Y, et al. Chinese Cases of Metachromatic Leukodystrophy with the Novel Missense Mutations in ARSA Gene. J Mol Neurosci. 2020 Jul 2. 10.1007/s12031-020-01643-3:[QxMD MEDLINE Link]. [Full Text].

15. Yang K, Zhang Y, Lou G, et al. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. [Genetic analysis of a patient with late infantile metachromatic leukodystrophy]. Case Reports. 2020 Feb 10. 37(2):152-155. [QxMD MEDLINE Link]. [Full Text].

16. Bibi F, Haider N, Din SU, et al. Sequence variants in three genes underlying leukodystrophy in Pakistani families. Int J Dev Neurosci. 2020 May 13. 80(5):380-388. [QxMD MEDLINE Link]. [Full Text].

17. Fenu S, Castellotti B, Farina L, Cavallaro T, Di Bella D, Benzoni C, et al. Saposin B deficiency as a cause of adult-onset metachromatic leukodystrophy. Neurology. 2019 Aug 13. 93 (7):310-312. [QxMD MEDLINE Link]. [Full Text].

18. Beerepoot S, Nierkens S, Boelens JJ, Lindemans C, Bugiani M, Wolf NI. Peripheral neuropathy in metachromatic leukodystrophy: current status and future perspective. Orphanet J Rare Dis. 2019 Nov 4. 14 (1):240. [QxMD MEDLINE Link]. [Full Text].

19. Frati G, Luciani M, Meneghini V, et al. Human iPSC-based models highlight defective glial and neuronal differentiation from neural progenitor cells in metachromatic leukodystrophy. Cell Death Dis. 2018 Jun 13. 9(6):698. [QxMD MEDLINE Link]. [Full Text].

20. Bergner CG, van der Meer F, Winkler A, et al. Microglia damage precedes major myelin breakdown in X-linked adrenoleukodystrophy and metachromatic leukodystrophy. Glia. 2019 Feb 11. 67(6):1196-1209. [QxMD MEDLINE Link]. [Full Text].

21. Estrov Y, Scaglia F, Bodamer OA. Psychiatric symptoms of inherited metabolic disease. J Inherit Metab Dis. 2000 Feb. 23(1):2-6. [QxMD MEDLINE Link]. [Full Text].

22. Fukutani Y, Noriki Y, Sasaki K, et al. Adult-type metachromatic leukodystrophy with a compound heterozygote mutation showing character change and dementia. Psychiatry Clin Neurosci. 1999 Jun. 53(3):425-8. [QxMD MEDLINE Link]. [Full Text].

23. Almarzooqi S, Quadri A, Albawardi A. Gallbladder Polyps in Metachromatic Leukodystrophy. Fetal Pediatr Pathol. 2018 Apr. 37(2):102-108. [QxMD MEDLINE Link]. [Full Text].

24. Koshu K, Ikeda T, Tamura D, et al. Gallbladder cancer with ascites in a child with metachromatic leukodystrophy. Brain Dev . 2020 Aug 24. S0387-7604(20):30216-3. [QxMD MEDLINE Link]. [Full Text].

25. Harrington M, Whalley D, Twiss J, et al. Insights into the natural history of metachromatic leukodystrophy from interviews with caregivers. Orphanet J Rare Dis. 2019 Apr 29. 14(1):89. [QxMD MEDLINE Link]. [Full Text].

26. Eichler FS. Metachromatic leukodystrophy and multiple sulfatase deficiency. Rosenberg RN, Pascual JM, eds. Rosenberg's Molecular and Genetic Basis of Neurological and Psychiatric Disease. 6th ed. Academic Press; 2020. Vol 1: 473-479. [Full Text].

27. Ahn H, Seo GH, Keum C, et al. Diagnosis of metachromatic leukodystrophy in a patient with regression and Phelan-McDermid syndrome. Brain Dev. 2020 May. 42(5):414-417. [QxMD MEDLINE Link]. [Full Text].

28. Mingbunjerdsuk D, Wong M, Bozarth X, Sun A. Co-occurrence of Metachromatic Leukodystrophy in Phelan-McDermid Syndrome. J Child Neurol. published online ahead of print, 2020 Sep 29. [QxMD MEDLINE Link]. [Full Text].

29. Lynch DS, Wade C, Paiva ARB, et al. Practical approach to the diagnosis of adult-onset leukodystrophies: an updated guide in the genomic era. J Neurol Neurosurg Psychiatry. 2019 May. 90(5):543-554. [QxMD MEDLINE Link]. [Full Text].

30. Morena F, Argentati C, Acquati S, et al. Toward Reference Intervals of ARSA Activity in the Cerebrospinal Fluid: Implication for the Clinical Practice of Metachromatic Leukodystrophy. J Appl Lab Med. [published online ahead of print, 2020 Sep 10]. [QxMD MEDLINE Link]. [Full Text].

31. Meikle PJ, Grasby DJ, Dean CJ. Newborn screening for lysosomal storage disorders. Mol Genet Metab. 2006 Aug. 88(4):307-14. [QxMD MEDLINE Link]. [Full Text].

32. Faerber EN, Melvin J, Smergel EM. MRI appearances of metachromatic leukodystrophy. Pediatr Radiol. 1999 Sep. 29(9):669-72. [QxMD MEDLINE Link]. [Full Text].

33. Wadhwa A, Chen Y, Holmqvist A, et al. Late Mortality after Allogeneic Blood or Marrow Transplantation for Inborn Errors of Metabolism: A Report from the Blood or Marrow Transplant Survivor Study-2 (BMTSS-2). Biol Blood Marrow Transplant. 2019 Feb 01. 25(2):328-334. [QxMD MEDLINE Link]. [Full Text].

34. van den Broek BTA, Page K, Paviglianiti A, et al. Early and late outcomes after cord blood transplantation for pediatric patients with inherited leukodystrophies. Blood Adv. 2018 Jan 04. 2(1):49-60. [QxMD MEDLINE Link]. [Full Text].

35. Wolf NI, Breur M, Plug B, et al. Metachromatic leukodystrophy and transplantation: remyelination, no cross-correction. Ann Clin Transl Neurol. 2020 Feb. 7(2):169-180. [QxMD MEDLINE Link]. [Full Text].

36. Krivit W. Allogeneic stem cell transplantation for the treatment of lysosomal and peroxisomal metabolic diseases. Springer Semin Immun. 2004. 26:119-132. [QxMD MEDLINE Link]. [Full Text].

37. Martin PL, Carter SL, Kernan NA. Results of the cord blood transplantation study (COBLT): outcomes of unrelated donor umbilical cord blood transplantation in pediatric patients with lysosomal and peroxisomal storage diseases. Biol Blood Marrow Transplant. 2006 Feb. 12(2):184-94. [QxMD MEDLINE Link]. [Full Text].

38. Beschle J, Döring M, Kehrer C, et al. Early clinical course after hematopoietic stem cell transplantation in children with juvenile metachromatic leukodystrophy. Mol Cell Pediatr. 2020 Sep 03. 7(1):12. [QxMD MEDLINE Link]. [Full Text].

39. Consiglio A, Quattrini A, Martino S, et al. In vivo gene therapy of metachromatic leukodystrophy by lentiviral vectors: correction of neuropathology and protection against learning impairments in affected mice. Nat Med. 2001 Mar. 7(3):310-6. [QxMD MEDLINE Link]. [Full Text].

40. Matzner U, Habetha M, Gieselmann V. Retrovirally expressed human arylsulfatase A corrects the metabolic defect of arylsulfatase A-deficient mouse cells. Gene Ther. 2000 May. 7(9):805-12. [QxMD MEDLINE Link]. [Full Text].

41. Penati R, Fumagalli F, Calbi V, Bernardo ME, Aiuti A. Gene therapy for lysosomal storage disorders: recent advances for metachromatic leukodystrophy and mucopolysaccaridosis I. J Inherit Metab Dis. 2017 Jul. 40 (4):543-554. [QxMD MEDLINE Link]. [Full Text].

42. Rosenberg JB, Kaminsky SM, Aubourg P, Crystal RG, Sondhi D. Gene therapy for metachromatic leukodystrophy. J Neurosci Res. 2016 Nov. 94 (11):1169-79. [QxMD MEDLINE Link]. [Full Text].

43. Calbi V, Fumagalli F, Consiglieri G, et al. Use of Defibrotide to help prevent post-transplant endothelial injury in a genetically predisposed infant with metachromatic leukodystrophy undergoing hematopoietic stem cell gene therapy. Bone Marrow Transplant. 2018 Jul. 53(7):913-917. [QxMD MEDLINE Link]. [Full Text].

44. Tucci F, Frittoli M, Barzaghi F, et al. Bone marrow harvesting from paediatric patients undergoing haematopoietic stem cell gene therapy. Bone Marrow Transplant. 2019 Dec. 54(12):1995-2003. [QxMD MEDLINE Link]. [Full Text].

45. Biffi A, Montini E, Lorioli L, Cesani M, Fumagalli F, Plati T. Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy. Science. 2013 Aug 23. 341(6148):1233158. [QxMD MEDLINE Link]. [Full Text].

46. Kawabata K, Migita M, Mochizuki H. Ex vivo cell-mediated gene therapy for metachromatic leukodystrophy using neurospheres. Brain Res. 2006 Jun 13. 1094(1):13-23. [QxMD MEDLINE Link]. [Full Text].

47. Matzner U, Herbst E, Hedayati K, et al. Enzyme replacement improves nervous system pathology and function in a mouse model for metachromatic leukodystrophy. Hum Mol Genet. 2005 May. 14(9):1139-1152. [QxMD MEDLINE Link]. [Full Text].

48. Simonis H, Yaghootfam C, Sylvester M, Gieselmann V, Matzner U. Evolutionary redesign of the lysosomal enzyme arylsulfatase A increases efficacy of enzyme replacement therapy for metachromatic leukodystrophy. Hum Mol Genet. 2019 Jun 1. 28(11):810-1821. [QxMD MEDLINE Link]. [Full Text].

49. van der Veldt N, van Rappard DF, van de Pol LA, van der Knaap MS, van Ouwerkerk WJR, Becher JG, et al. Intrathecal baclofen in metachromatic leukodystrophy. Dev Med Child Neurol. 2019 Feb. 61 (2):232-235. [QxMD MEDLINE Link]. [Full Text].

50. Í Dali C, Sevin C, Krägeloh-Mann I, et al. Safety of intrathecal delivery of recombinant human arylsulfatase A in children with metachromatic leukodystrophy: Results from a phase 1/2 clinical trial. Mol Genet Metab. 2020 Jul 16. S1096-7192(20):30152-9. [QxMD MEDLINE Link]. [Full Text].

51. Troy S, Wasilewski M, Beusmans J, Godfrey CJ. Pharmacokinetic Modeling of Intrathecally Administered Recombinant Human Arylsulfatase A (TAK-611) in Children With Metachromatic Leukodystrophy. Clin Pharmacol Ther. 2020 Jun. 107(6):1394-1404. [QxMD MEDLINE Link]. [Full Text].

52. Givogri MI, Galbiati F, Fasano S. Oligodendroglial progenitor cell therapy limits central neurological deficits in mice with metachromatic leukodystrophy. J Neurosci. 2006 Mar 22. 26(12):3109-19. [QxMD MEDLINE Link]. [Full Text].

Anna V Blenda, PhD Clinical Associate Professor, Department of Biomedical Sciences, University of South Carolina School of Medicine, Greenville

Anna V Blenda, PhD is a member of the following medical societies: American Association for Cancer Research, American College of Medical Genetics and Genomics, American Society for Microbiology

Disclosure: Nothing to disclose.

Mary L Windle, PharmD Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

Luis O Rohena, MD, PhD, FAAP, FACMG Deputy Chief, Department of Pediatrics, Chief, Medical Genetics, San Antonio Military Medical Center; Associate Professor of Pediatrics, Uniformed Services University of the Health Sciences, F Edward Hebert School of Medicine; Associate Professor of Pediatrics, University of Texas Health Science Center at San Antonio

Luis O Rohena, MD, PhD, FAAP, FACMG is a member of the following medical societies: American Academy of Pediatrics, American Chemical Society, American College of Medical Genetics and Genomics, American Society of Human Genetics

Disclosure: Nothing to disclose.

Karl S Roth, MD Retired Professor and Chair, Department of Pediatrics, Creighton University School of Medicine

Karl S Roth, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Pediatrics, American College of Nutrition, American Pediatric Society, American Society for Nutrition, American Society of Nephrology, Association of American Medical Colleges, Medical Society of Virginia, New York Academy of Sciences, Sigma Xi, The Scientific Research Honor Society, Society for Pediatric Research, Southern Society for Pediatric Research

Disclosure: Nothing to disclose.

Robert D Steiner, MD, FAAP, FACMG Professor (Clinical), Department of Pediatrics, University of Wisconsin School of Medicine and Public Health; Editor-in-Chief, Genetics in Medicine; Chief Medical Officer, PreventionGenetics

Robert D Steiner, MD, FAAP, FACMG is a member of the following medical societies: American Academy of Pediatrics, American Association for the Advancement of Science, American College of Medical Genetics and Genomics, American Society of Human Genetics, Society for Inherited Metabolic Disorders, Society for Pediatric Research, Society for the Study of Inborn Errors of Metabolism

Disclosure: Serve(d) as a director, officer, partner, employee, advisor, consultant or trustee for: PreventionGenetics-part of Exact Sciences; Acer Therapeutics; DNARx; Best Doctors; PTC Therapeutics; CTX Alliance; Leadiant' Travere<br/>Received income in an amount equal to or greater than $250 from: Marshfield Clinic; PreventionGenetics-part of Exact Sciences; Acer Therapeutics; PTC Therapeutics; DNARx; Leadiant; Travere.

Theodore Moore, MD, MS Professor and Chief, Department of Pediatrics, Division of Pediatric Hematology/Oncology, Director of Pediatric Blood and Marrow Transplant Program, University of California, Los Angeles, David Geffen School of Medicine

Theodore Moore, MD, MS is a member of the following medical societies: American Society of Pediatric Hematology/Oncology, Society for Pediatric Research, American Society for Blood and Marrow Transplantation, Western Society for Pediatric Research, American Society of Hematology

Disclosure: Nothing to disclose.

David Flannery, MD, FAAP, FACMG Vice Chair of Education, Chief, Section of Medical Genetics, Professor, Department of Pediatrics, Medical College of Georgia

David Flannery, MD, FAAP, FACMG is a member of the following medical societies: American Academy of Pediatrics, American College of Medical Genetics and Genomics

Disclosure: Nothing to disclose.

Alan K Ikeda, MD Interim Medical Director, Director of Oncology, Children's Specialty Center of Las Vegas

Alan K Ikeda, MD is a member of the following medical societies: American Academy of Pediatrics, American Society for Blood and Marrow Transplantation, American Society of Pediatric Hematology/Oncology

Disclosure: I own stocks in various pharmaceutical companies. This varies on a given week for: multiple and varies.

• Print this section
• Print the entire contents of
• Print the entire contents of article